Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.04 +1.0%	$1.26	$0.86 ▼ $3.78	$227.48M	0.35	4.39 million shs	7.99 million shs
DBVT DBV Technologies	$9.91 +1.0%	$9.68	$2.20 ▼ $12.78	$271.44M	-0.58	209,828 shs	18,918 shs
FDMT 4D Molecular Therapeutics	$6.67 +8.5%	$4.50	$2.23 ▼ $17.41	$309.02M	2.83	880,740 shs	1.41 million shs
RPHM Reneo Pharmaceuticals	$1.82	$1.64	$0.98 ▼ $9.21	$60.84M	0.21	250,384 shs	437,523 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-8.04%	-19.53%	+8.10%	-56.36%
DBVT DBV Technologies	+2.55%	+0.93%	-9.17%	-14.55%	+122.95%
FDMT 4D Molecular Therapeutics	+11.21%	+1.65%	+43.69%	+96.49%	-59.00%
RPHM Reneo Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+35.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.5417 of 5 stars	3.4	2.0	0.0	0.0	2.4	2.5	0.6
DBVT DBV Technologies	3.545 of 5 stars	3.4	5.0	0.0	0.0	3.1	2.5	0.6
FDMT 4D Molecular Therapeutics	2.3023 of 5 stars	3.3	3.0	0.0	0.0	1.6	1.7	0.6
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	711.97% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	48.84% Upside
FDMT 4D Molecular Therapeutics	2.64	Moderate Buy	$30.40	355.77% Upside
RPHM Reneo Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RPHM, FDMT, DBVT, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	FDMT 4D Molecular Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
8/12/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	$2.01 per share	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$3.15 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	7,725.53	N/A	N/A	$11.05 per share	0.60
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	$2.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/13/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	N/A
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-594,375.81%	-38.38%	-35.02%	8/14/2025 (Estimated)
RPHM Reneo Pharmaceuticals	-$77.39M	-$2.17	N/A	N/A	N/A	N/A	-62.52%	-56.36%	N/A

Latest RPHM, FDMT, DBVT, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/11/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.88	-$0.98	-$0.10	-$0.98	$0.52 million	$0.01 million
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
DBVT DBV Technologies	N/A	2.45	2.45
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
RPHM Reneo Pharmaceuticals	N/A	57.86	57.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
DBVT DBV Technologies	71.74%
FDMT 4D Molecular Therapeutics	99.27%
RPHM Reneo Pharmaceuticals	90.98%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
DBVT DBV Technologies	1.44%
FDMT 4D Molecular Therapeutics	9.60%
RPHM Reneo Pharmaceuticals	17.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
RPHM Reneo Pharmaceuticals	30	33.43 million	27.44 million	Optionable

RPHM, FDMT, DBVT, and ALLO Headlines

Recent News About These Companies

Onkure Therapeutics Inc (OKUR)

December 4, 2024 | investing.com

Cormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals Shares

October 11, 2024 | finance.yahoo.com

Deep Track Capital's Strategic Investment in Reneo Pharmaceuticals

October 11, 2024 | finance.yahoo.com

Carlyle Group Inc. Reduces Stake in Reneo Pharmaceuticals Inc.

October 10, 2024 | finance.yahoo.com

Reneo Pharmaceuticals: Navigating Financial Challenges and Corporate Changes

October 9, 2024 | finance.yahoo.com

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

October 4, 2024 | globenewswire.com

Baosheng Media Gr (NASDAQ:BAOS) Stock Quotes, Forecast and News Summary

October 3, 2024 | benzinga.com

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

October 2, 2024 | globenewswire.com

Braden Michael Leonard Acquires 29,600 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Stock

September 27, 2024 | insidertrades.com

Braden Michael Leonard Purchases 55,300 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Stock

September 20, 2024 | insidertrades.com

Reneo Pharmaceuticals Inc (RPHM) Stock: More Resilient Than It Appears

September 15, 2024 | bovnews.comB

Color Star Tech (NASDAQ:ADD) Stock Quotes, Forecast and News Summary

September 12, 2024 | benzinga.com

Reneo Pharmaceuticals insider buys shares worth over $380k

August 16, 2024 | investing.com

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Braden Michael Leonard Acquires 171,339 Shares

August 15, 2024 | insidertrades.com

RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q2 2024

August 13, 2024 | investorplace.com

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 13, 2024 | globenewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

June 26, 2024 | globenewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

June 24, 2024 | prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders

June 21, 2024 | globenewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

June 21, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPHM, FDMT, DBVT, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.04 +0.01 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 0.00 (0.00%)

As of 07:45 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

DBV Technologies NASDAQ:DBVT

$9.91 +0.10 (+1.02%)

Closing price 03:58 PM Eastern

Extended Trading

$10.00 +0.09 (+0.90%)

As of 06:04 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

4D Molecular Therapeutics NASDAQ:FDMT

$6.67 +0.52 (+8.46%)

Closing price 04:00 PM Eastern

Extended Trading

$6.57 -0.10 (-1.50%)

As of 07:48 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Reneo Pharmaceuticals NASDAQ:RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time